Trial
NCT04886063
Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
LeonaBio
Collaborators
—
Condition
Alzheimer Disease
Intervention
ATH-1017
Why stopped
ATH-1017-AD-0203 was terminated after the Ph2/3 parent trial (LIFT-AD; NCT04488419) did not meet its primary endpoint, the GST score.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-01